and ST. GALLEN, Switzerland.
CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology leader CSL Limited (ASX: CSL; USOTC: CSLLY), today published the offer prospectus regarding its public tender offer for all publicly held registered shares of Vifor Pharma Ltd. (SIX:VIFN; ISIN:CH0364749348), a global specialty pharmaceutical company with leadership in Iron Deficiency, Nephrology & Cardio-Renal Therapies, as indicated in the pre-announcement of the public tender offer published by CSL Limited on 14 December 2021.
The transaction has been unanimously approved by both companies’ Boards of Directors. The offer price for each registered share of Vifor Pharma Ltd. is USD 179.25 in cash. The public tender offer is subject to the offer conditions set forth in the offer prospectus, which is available on the website www.CSLtransaction.com.
The main offer period is expected to commence on 2 February 2022 and end at 4:00 p.m. Swiss time on 2 March 2022. A detailed indicative timetable is set forth in the offer prospectus.
